Table 1.
Clinical and laboratory data of the study population.
| Variable | CCS (n = 32) |
STEMI (n = 18) |
OHCA-STEMI (n = 17) |
P-ANOVA | * p Value CCS vs. STEMI |
* p Value STEMI vs. OHCA-STEMI |
|---|---|---|---|---|---|---|
| Demographic and clinical characteristics | ||||||
| Age, years | 64.1 ± 8.1 | 67.2 ± 10.8 | 58.5 ± 10.5 | 0.03 | 0.42 | 0.02 |
| BMI, Kg/m2 | 26.0 ± 3.0 | 26.5 ± 3.3 | 27.1 ± 4.4 | 0.71 | 0.70 | 1.00 |
| RBC, 106/μL | 4.8 ± 0.4 | 4.0 ± 0.9 | 4.5 ± 0.8 | 0.0003 | 0.0001 | 0.03 |
| WBC, 103/μL | 7.7 ± 1.9 | 11.6 ± 1.9 | 13.0 ± 4.1 | <0.0001 | <0.0001 | 0.37 |
| PLT, 103/μL | 236.6 ± 44.3 | 242.4 ± 53.7 | 247.1 ± 61.3 | 0.053 | 0.08 | 1.00 |
| Hemoglobin (g/dL) | 14.6 ± 1.2 | 13.3 ± 2.0 | 14.2 ± 1.8 | 0.01 | 0.007 | 0.08 |
| Total cholesterol, mg/dL | 159.9 ± 30.4 | 172.4 ± 42.9 | 171.4 ± 43.2 | 0.32 | 0.22 | 0.55 |
| HDL cholesterol, mg/dL | 46.4 ± 10.4 | 41.5 ± 8.8 | 39.7 ± 9.4 | 0.10 | 0.12 | 1.00 |
| LDL cholesterol, mg/dL | 90.4 ± 28.6 | 106.1 ± 39.2 | 113.7 ± 31.9 | 0.08 | 0.09 | 0.98 |
| Triglycerides, mmol/L | 71.0 ± 63.4 | 128.8 ± 60.6 | 136.6 ± 72.8 | 0.29 | 0.26 | 0.96 |
| Glycemia, mg/dL | 109.4 ± 15.6 | 181.9 ± 102.3 | 206.8 ± 122.5 | <0.0001 | 0.001 | 0.30 |
| Creatinine, mg/dL | 1.5 ± 0.2 | 1.1 ± 0.3 | 1.1 ± 0.3 | 0.18 | 0.99 | 0.18 |
| CRP, mg/L | 0.7 (0.5–2.3) | 2.8 (1.7–3.8) | 2.2 (0.9;4.4) | 0.04 | 0.03 | 0.59 |
| hs Tnl max, μg/L | / | 16.3 (12.9–99.6) |
80.3 (35.6–1742.7) |
0.26 | / | 0.26 |
| Time-to-Pres (h) | / | 3.36 ± 2.2 | 5.24 ± 7.38 | 0.33 | / | 0.33 |
| anterior AMI, n (%) | / | 10 (55.6%) | 10 (58.8%) | 0.78 | / | 0.78 |
| Smokers, n (%) | 6 (71.9%) | 7 (38.9%) | 6 (35.3%) | 0.84 | 0.98 | 0.79 |
| Diabetes, n (%) | 6 (19.4%) | 6 (33.3%) | 5 (29.4%) | 0.54 | 0.51 | 0.99 |
| Hypertension, n (%) | 23 (71.9%) | 12 (66.7%) | 9 (52.9%) | 0.66 | 0.66 | 1.00 |
| Familiarity, n (%) | 4 (22.2%) | 4 (22.2%) | 2 (11.8%) | 0.01 | 0.11 | 0.43 |
| Dyslipidemia, n (%) | 20 (62.5%) | 9 (50%) | 5 (29.4%) | 0.15 | 0.49 | 0.62 |
| Pharmacological treatments | ||||||
| ACE inhibitors, n (%) | 21 (67.7%) | 5 (27.8%) | 8 (47.1%) | 0.02 | 0.008 | 0.20 |
| Statin, n (%) | 23 (74.2%) | 2 (11.1%) | 3 (17.6%) | <0.0001 | <0.0001 | 0.74 |
| β-blockers, n (%) | 19 (61.3%) | 4 (22.2%) | 4 (23.5%) | 0.006 | 0.007 | 0.83 |
| Ca channel blockers, n (%) | 5 (16.1%) | 1 (5.6%) | 1 (5.9%) | 0.39 | 0.46 | 0.99 |
| Hypoglycemics, n (%) | 4 (12.9%) | 5 (27.8%) | 2 (11.8%) | 0.44 | 0.36 | 0.49 |
| Thienopyridine, n (%) | 11 (35.5%) | 0 (0%) | 1 (5.9%) | 0.002 | 0.003 | 0.76 |
| Aspirin, n (%) | 27 (87.1%) | 3 (16.7%) | 3 (17.6%) | <0.0001 | <0.0001 | 0.78 |
BMI: body mass index, RBC: red blood cells; WBC: white blood cells; PLT: platelet; HDL: high-density lipoprotein; LDL: low-density lipoprotein; CRP: C-reactive protein; hs Tnl: high-sensitivity troponin; ACE: angiotensin-converting enzyme; CCS: chronic coronary syndrome; AMI: acute myocardial infarction; STEMI: ST-segment elevation myocardial infarction; OHCA-STEMI: STEMI experiencing resuscitated out-of-hospital cardiac arrest. * age-adjusted p value with Dunnett correction for multiple comparisons.